Ecoool made a good point here
"I still fear the big risk is whoever the Prof is dealing with from a partnering point of view doing the numbers and realizing that this is a product capable of adding $US30 billion to their valuation right NOW (that's how much Gilead went up on Remdesivir and Moderna added a similar amount before falling back) - yet they can buy the whole thing for $US1.5 billion and get all the other P3 trials and products for free.That's ridiculously attractive for a big pharma, and the pressure point is now, before they sign a contract that would push the MSB price significantly higher and make a takeover much more expensive."
Something to think about
MSB Trading - 2020, page-11304
-
- There are more pages in this discussion • 11,857 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
-0.050(3.83%) |
Mkt cap ! $1.432B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.30 | $1.17 | $21.32M | 17.21M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 5460 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.26 | 978 | 1 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |